Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
2024-02-13 5:06 pm Purchase | 13G | HAEMONETICS CORP HAE | VANGUARD GROUP INC | 5,406,309 10.65% | 163,473 (+3.12%) | View |
2024-02-13 3:28 pm Sale | 13G | HAEMONETICS CORP HAE | Neuberger Berman Group LLC | 3,531,181 6.96% | -342,255 (-8.84%) | View |
2024-02-09 5:49 pm Purchase | 13G | HAEMONETICS CORP HAE | Capital Research Global Investors | 6,523,568 12.9% | 567,504 (+9.53%) | View |
2024-02-08 10:21 am Sale | 13G | HAEMONETICS CORP HAE | WELLINGTON MANAGEMENT GROUP LLP | 3,268,083 6.44% | -766,670 (-19.00%) | View |
2024-01-23 4:13 pm Purchase | 13G | HAEMONETICS CORP HAE | BlackRock Inc. BLK | 6,056,881 11.9% | 158,261 (+2.68%) | View |
2023-02-13 3:32 pm Purchase | 13G | HAEMONETICS CORP HAE | Capital Research Global Investors | 5,956,064 11.8% | 504,058 (+9.25%) | View |
2023-02-10 2:10 pm Sale | 13G | HAEMONETICS CORP HAE | Neuberger Berman Group LLC | 3,873,436 7.65% | -3,085 (-0.08%) | View |
2023-02-09 11:22 am Purchase | 13G | HAEMONETICS CORP HAE | VANGUARD GROUP INC | 5,242,836 10.36% | 47,641 (+0.92%) | View |
2023-02-06 3:00 pm Sale | 13G | HAEMONETICS CORP HAE | WELLINGTON MANAGEMENT GROUP LLP | 4,034,753 7.97% | -1,502,785 (-27.14%) | View |
2023-01-26 08:52 am Unchanged | 13G | HAEMONETICS CORP HAE | BlackRock Inc. BLK | 5,898,620 11.7% | 0 (Unchanged) | View |
2023-01-20 3:00 pm Sale | 13G | HAEMONETICS CORP HAE | BlackRock Inc. BLK | 5,898,620 11.7% | -793,726 (-11.86%) | View |
2022-10-11 10:07 am Purchase | 13G | HAEMONETICS CORP HAE | VANGUARD GROUP INC | 5,195,195 10.12% | 314,259 (+6.44%) | View |
2022-04-08 11:19 am Purchase | 13G | HAEMONETICS CORP HAE | Capital Research Global Investors | 5,452,006 10.7% | 3,402,873 (+166.06%) | View |
2022-02-14 2:29 pm Purchase | 13G | HAEMONETICS CORP HAE | Neuberger Berman Group LLC | 3,876,521 7.59% | 1,043,472 (+36.83%) | View |
2022-02-11 12:22 pm Sale | 13G | HAEMONETICS CORP HAE | Capital Research Global Investors | 2,049,133 4% | -726,503 (-26.17%) | View |
2022-02-10 08:16 am Purchase | 13G | HAEMONETICS CORP HAE | VANGUARD GROUP INC | 4,880,936 9.55% | 28,654 (+0.59%) | View |
2022-02-10 07:48 am Purchase | 13G | HAEMONETICS CORP HAE | WELLINGTON MANAGEMENT GROUP LLP | 5,537,538 10.83% | 447,237 (+8.79%) | View |
2022-02-04 09:27 am Purchase | 13G | HAEMONETICS CORP HAE | WELLINGTON MANAGEMENT GROUP LLP | 5,090,301 9.96% | 2,837,909 (+126.00%) | View |
2022-01-26 8:18 pm Unchanged | 13G | HAEMONETICS CORP HAE | BlackRock Inc. BLK | 6,692,346 13.1% | 0 (Unchanged) | View |
2022-01-25 11:15 am Purchase | 13G | HAEMONETICS CORP HAE | BlackRock Inc. BLK | 6,692,346 13.1% | 713,043 (+11.93%) | View |